

Mahajan, Vinay

From: Office, BadhriSrinivasan (Gen)
Sent: Tuesday, November 15, 2022 4:36 PM
Subject: Organizational announcement - Global Clinical Operations (GCO) LT-1 appointments

Dear GDO,

In October we updated you on our GDO Transformation (Project Ambition) and the output of our redesign activity of clinical operations. It is still our intention to share with you as much as we can, as soon as we can, and as transparently as we can.

We are now able to provide more information about the roles, capabilities and responsibilities of the teams reporting into the new GCO Leadership Team. Having conducted a thorough recruitment process, we are excited to share with you the leaders appointed to these new roles.

You will have an opportunity to meet these new leaders and hear about their areas of responsibility at [the information sessions this week](#). In the meantime, please join us in congratulating them and wishing them success with their new responsibilities.

Click on the links below to read the announcement, or scroll-down:

- [Program Strategy & Planning \(PSP\) announcement](#)
- [Study & Site Operations \(SSO\) announcement](#)
- [Clinical Data Operations \(CDO\) announcement](#)
- [Vendor Partnerships & Governance \(VPG\) announcement](#)
- [Process, Training & GCP Compliance \(PTC\) announcement](#)
- [Strategy, Business Insights & Technology \(SIT\) announcement](#)

We appreciate that many of you have had to cope with ambiguity about the future shape, structure, and ways of working of GCO, and are keen to get more information as soon as possible. We are working hard to ensure that we share as much as we can, as soon as we can.

A transformation of this scale brings with it complexity in how we update you. In the 'all GDO/GCO session' this week, we will outline our efforts to balance the need to move quickly with our need to ensure our rollout is successful and aligned with our legal, people and financial responsibilities.

Thank you for your ongoing patience, understanding and professionalism.

Badhri and the GCO Leadership Team

Program Strategy & Planning (PSP) announcement

Kevin Carl is pleased to introduce the Program Strategy & Planning leadership team, effective January 1, 2023:

- **Amy Shah** is appointed as **GCO Development Unit Head – Neuroscience & BD&L**
- **Paul Robinson** is appointed as **GCO Development Unit Head – Immunology**
- **Richard Yu** is appointed as **GCO Development Unit Head – Global Health & Ophthalmology**
- **Henry Bennett** is appointed as **GCO Development Unit Head – Oncology & Hematology**
- **Zdenek Zencak** is appointed as **GCO Development Unit Head – CRM**
- **Dana Iommazzo** is appointed as **Head of Clinical Operations Program Management**
- **Frederique Ahlin-Goulart** is appointed as **Head GCO Innovation**

- **John Woodson** is appointed as **Head of Budget and Resource Management**
- **Guillaume Carbonneau** is confirmed as **Head Health Data Insights & Design**
- **Gwen Woods** is confirmed as **Head Strategy and Operations – PSP**

As already announced in October 2022, **Stephen Eason** is confirmed as **Global Head Regulatory Writing and Submissions**.

During the transition period we will ensure business continuity through retaining existing reporting lines: The GTPHs in the existing GDO Portfolio Execution Organization (PEO) will continue to report to their Current Trial Management DUH, who will remain the primary representative on the DULT. The newly appointed GCO Program Strategy & Planning (PSP) DU Heads will assume responsibilities at the end of Q1 2023, at the earliest, unless notified differently via official communication.

Study & Site Operations (SSO) announcement

Rosemary Rebuli is pleased to introduce the Study & Site Operations leadership team, effective January 1, 2023:

- **Vittoria Sparacio** is confirmed as **Head Clinical Document Governance & Management**
- **Alexander Prodoehl** is appointed as **Hub Head EMEA**
- While we continue the search for a permanent **Hub Head ASIA**, **José Barradas** has kindly agreed to take the position on an *ad interim* basis
- **Ashley Duff** is confirmed as **Region US Head**
- **Paula Llambias** is confirmed as **Region LACan Head**
- **Matthieu Ruffin** is appointed as **Head of Study Leadership**
- While we continue the search for a permanent **Head Study Start-Up**, **Branda Wilhoite** has kindly agreed to take the position on an *ad interim* basis
- We continue the search for our **Head Strategy & Operations - SSO** and we will update you about the outcome of the selection process in future communications

During the transition period, we will ensure business continuity through retaining existing reporting lines: The GTPHs in the existing GDO Portfolio Execution Organization (PEO) will continue to report to their Current Trial Management DUH, who will remain the primary representative on the DULT. The newly appointed GCO Program Strategy & Planning (PSP) DU Heads will assume responsibilities at the end of Q1 2023, at the earliest, unless notified differently via official communication.

Clinical Data Operations (CDO) announcement

Arno Tellmann is pleased to introduce the Clinical Data Operations leadership team, effective January 1, 2023:

- **Jagadeesh Rudraswamymath** is appointed as **Head Clinical Data Acquisition & Management**
- **Arnab Sengupta** is appointed as **Head Clinical Data Strategy**
- **Guillaume Breton** is confirmed as **Head Statistical Programming**
- **Chitresh Kasliwal** is confirmed as **Head Clinical Scientific Experts**
- **Jason Housley** is confirmed as **Head Clinical Data Standards**
- **Sarvesh Singh** is confirmed as **Head Strategy & Operations – CDO**
- **Yanli Chang** is confirmed as **Head Clinical Data Operations China**
- **Makoto Abe** is confirmed as **Head Clinical Data Operations Japan**

For those of you that currently report into the leaders above, you will continue to report to your current manager until notified of new reporting lines, by the end of Q1 2023.

Vendor Partnerships & Governance (VPG) announcement

Eileen Kelly is pleased to introduce the Vendor Partnerships & Governance leadership team, effective January 1, 2023:

- **Rebecca Gottschalk** is appointed as **Head Vendor Program Managers**

- **Sonya Ferguson** is appointed as **Head Vendor Alliance – Laboratory**
- **Daniel Ernst** is appointed as **Head Vendor Alliance – Country**
- **Bryan Kraker** is appointed as **Head Vendor Alliance - Tech Enabled Services**
- **Jenny Browne** is appointed as **Head Vendor Alliance - Full Service and BD&L**
- **Priya Pawar** is appointed as **Head Vendor Alliance - Functional Service Provider**
- **Florencia Velasco** is appointed as **Head Vendor Alliance - Patient Recruitment & Retention**
- While we continue the search for a permanent **Head Vendor Program Leads**, **Daniel Ernst** has kindly agreed to take the position on an *ad interim* basis, starting on January 1, 2023
- We continue the search for our **Head Strategy & Operations – VPG** and our **Head Vendor Alliance - Supply Chain & Logistics** and we will update you about the outcome of the selection processes in future communications.

For those of you that currently report into the leaders above, you will continue to report to your current manager until notified of new reporting lines, by the end of Q1 2023.

Process, Training & GCP Compliance (PTC) announcement

Andy Cochrane is pleased to introduce the Process, Training & GCP Compliance leadership team, effective January 1, 2023:

- **Grant Simmons** is appointed as **Head GCO Process Excellence**
- **Audrey Laplanche** is appointed as **Head GCP Compliance**
- While we continue the search for a permanent **Head Clinical Operations Learning**, **Petra Jaeger** has kindly agreed to take the position on an *ad interim* basis.
- We continue the search for our **Head Strategy and Operations - PTC** and we will update you about the outcome of the selection process in future communications

For those of you that currently report into the leaders above, you will continue to report to your current manager until notified of new reporting lines, by the end of Q1 2023.

Strategy, Business Insights & Technology (SIT) announcement

Thomas Dieffenbronn is pleased to introduce the Strategy, Business Insights & Technology leadership team, effective January 1, 2023:

- **Carla Santos** is appointed as **Head Technology Platform SSO**
- **Robert McGregor** is appointed as **Head Technology Platform PSP/Emergent**
- **Annie Hilliard** is appointed as **Head Technology Platform CDO**
- **Rudi Ager** is appointed as **Head Technology Integration and Standards**
- **Suraj Sreenivasan** is appointed as **Head Business Analytics**
- **Oliver Schaetzle** is confirmed as **Head Non-Drug Project Delivery**
- **Jacqueline Lisa** is confirmed as **Head GCO Transformation**

As already announced in October 2022:

- **Dan Dietrich** is confirmed as **Global Head Risk, Resilience and Insights**
- **Guyline Vachon** is confirmed as **Global Head Strategy & Operations**

For those of you that currently report into the leaders above, you will continue to report to your current manager until notified of new reporting lines, by the end of Q1 2023.

For internal use only and not to be shown, distributed or disseminated outside of Novartis

Sent to: All GDO internal

